Micafungin Accord (Micafungin)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, preventing synthesis of β‑(1,3)‑D‑glucan, a key component of the fungal cell wall. This weakens the wall, leading to cell lysis and death of susceptible fungi.

The dose of Micafungin Accord is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. No standard dose is provided here.

Safety data for micafungin in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so clinicians must weigh potential benefits against possible risks before prescribing to pregnant or nursing patients.

To order, submit an enquiry on the Micafungin Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Micafungin belongs to the echinocandin class, which differs from azole antifungals such as fluconazole. Echinocandins have a unique mechanism targeting the fungal cell wall, often offering activity against azole‑resistant Candida species and a lower risk of drug‑drug interactions, though they require intravenous administration.

Micafungin Accord should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution before use.

Micafungin Accord is administered by intravenous infusion. The infusion is typically given over a period of 30‑60 minutes, depending on the clinical protocol and patient tolerance, under the supervision of qualified healthcare personnel.

Serious adverse events include hepatotoxicity, severe hypersensitivity reactions such as anaphylaxis, acute renal failure, and rare skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for signs of liver dysfunction, allergic responses, and renal impairment.

Micafungin Accord should be avoided in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment or uncontrolled renal disease, and it should be used only after risk‑benefit assessment in pregnant or lactating women.